Phase 2
Completed N=71
Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer
Source: ClinicalTrials.gov NCT00456599 ↗Enrolled (actual)
71
Serious AEs
39.4%
Results posted
Apr 2014
Primary outcomePrimary: Two-year Disease Free Survival. — 26.1 percentage of patients
Summary
This study will examine a sequence of treatments including pre-operative chemotherapy and radiation, surgery and post-operative chemotherapy for resectable pancreatic cancer.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Two-year Disease Free Survival. |
26.1 | — |
| SECONDARY Time to Treatment Failure |
10.4 | — |
| SECONDARY Overall Survival |
18.2 | — |
Eligibility Criteria
Inclusion Criteria
- Patients must have cytologic or histologic confirmation of carcinoma arising in the pancreas.
- Patients must be deemed resectable or borderline resectable based on criteria in section 4.2 prior to registration.
- Patients must have an expected life expectancy of at least 12 weeks and a Zubrod performance status of 1500/mm3, platelets > 100,000/mm3, serum Cr grade 2 are ineligible.
- Pregnant or nursing women are ineligible and patients of reproductive potential must agree to use an effective contraceptive method during participation in this trial and for 6 months after trial.
Data sourced from ClinicalTrials.gov (NCT00456599). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.